Physician profile
John D Betteridge
NPI 1447354410
$309,604.00
in general payments reported to CMS, 2019-2025
34 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $14K · 2021: $29K · 2022: $21K · 2023: $28K · 2024: $73K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Travel and Lodging: $20K · Consulting Fee: $8,100 · Food and Beverage: $7,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,125.50 |
| Travel and Lodging | $19,651.32 |
| Consulting Fee | $8,100.00 |
| Food and Beverage | $7,516.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154,623.06 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Pfizer INC. | $77,267.35 | 2019-2025 | |
| Janssen Biotech, INC. | $70,482.29 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $4,050.00 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $547.92 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $547.62 | 2019-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $274.80 | 2021-2024 | Zeposia |
| Genzyme Corporation | $200.71 | 2022-2025 | |
| Celltrion USA INC. | $164.61 | 2025 | Vegzelma |
| Lilly USA, LLC | $146.17 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $145.36 | 2023-2024 | Ibsrela |
| Fresenius Kabi USA, LLC | $132.22 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $110.60 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $108.75 | 2019-2023 | Dificid |
| Novo Nordisk INC | $103.39 | 2025 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $82.06 | 2022-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $79.14 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $74.91 | 2019-2023 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.23 | 2023 | Cyltezo |
| Amgen INC. | $49.71 | 2023 | Amjevita, Avsola |
| Boston Scientific Corporation | $47.55 | 2024-2025 | Cre Pro |
| Phathom Pharmaceuticals, INC. | $44.92 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $42.07 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $29.71 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $25.99 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $24.58 | 2024 | Iqirvo |
| Qol Medical, LLC | $23.74 | 2022 | |
| Capsovision, INC. | $21.78 | 2024 | Capsocam Plus |
| Ucb, INC. | $18.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.84 | 2022 | |
| Sandoz INC. | $16.24 | 2023 | Hyrimoz |
| Shionogi INC | $15.73 | 2019 | |
| Romark Laboratories, Lc | $13.14 | 2019 | |
| Shire North American Group INC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Betteridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.